Biodynes™ EMPP
Extracellular Matrix Promoting Peptone

INCI Name: Water & Saccharomyces Ferment Lysate Filtrate
SAP Code#: 136460

Key Product Attributes:
- Stimulates production of soluble elastin
- Anti-wrinkle
- Line minimizing

Background Information
The extrinsic and intrinsic aging of skin leads to several visible changes – sagging, wrinkles and loss of elasticity.\(^1\)\(^2\) In addition to these visible changes, there is a profound deterioration of the extracellular matrix.\(^3\) The extracellular matrix of human skin is comprised of Collagens, Elastic Fibers (of which elastin is a major component) and the Basement membrane associated macromolecules such as proteoglycans, fibronectin and laminin.\(^4\) Cosmetics is the art and science of visibly improving these signs of age.
It has been demonstrated that orally and topically applied glycosaminoglycans and proteoglycans can stimulate the production of elastin. The reason for this effect is that these basement membrane proteins can act as messengers that can up-regulate the genes that influence the production of collagen and elastin. In particular, glycosaminoglycans are of particular interest, as these types of peptides can be obtained from non-animal sources such as biofermentation reactions and marine-based sources. Biodynes™ EMPP is a new biofermentation lysate that has been developed by selectively modifying the nutritional peptone used to grow Saccharomyces cerevisiae by the addition of low molecular weight GAGs. Biodynes™ EMPP is also known as Biodynes™ Extracellular Matrix Promoting Peptone.

**Technical Information**

*In Vitro - Fastin Elastin Stain Testing*

**Full Thickness Tissue Model**

To demonstrate the unique functionality of Biodynes™ EMPP, we have developed a new in vitro testing methodology for measuring the ability of active ingredients to stimulate the formation of soluble elastin from cell cultures. The method for testing the ability of Biodynes™ EMPP to stimulate elastin production is shown below, Figure 1.

Ascorbic acid is known to stimulate the production of elastin in human skin and was chosen as the positive control for this study. It was necessary, however, to add additional ascorbic acid after 24 hours of testing as the half-life of ascorbic acid is quite short. Negative controls were untreated tissue. It can be seen below that 0.1% Biodynes™ EMPP indeed stimulates the production of soluble elastin in vitro in full thickness human skin tissue model, Figure 3.

**Results and Discussion**

Production of elastin begins within the growing cells of the dermis and epidermis through the production of soluble elastin precursors known as tropoelastin, Figure 1. In order to stimulate the skin to produce more elastin, products must stimulate the production of these soluble elastin precursors. Therefore, testing for the production of soluble elastin precursors was felt to be indicative of the ability of the skin to produce additional insoluble elastin fibers.
**In Vitro - Stain Testing on Human Fibroblasts**

Using the stain testing outlined for the MatTek full thickness tissue, Biodynes™ EMPP was also tested for measuring soluble elastin production in human fibroblasts. The results of the study are shown below in Figure 4.

**Fig. 4**

The average production of soluble elastin in human skin fibroblasts in micrograms/ml of culture media. The results (run in triplicate) include: the control fibroblast cultures that were not treated, fibroblast cells grown in the presence of 0.1 wt% of Biodynes™ TRF™ and fibroblast cells grown in the presence of 0.1 wt% of Biodynes™ EMPP.

**Results and Discussion**

From the data, it can be seen that the presence of 0.1 wt% of Biodynes™ EMPP can improve the synthesis of soluble elastin in human fibroblasts by nearly 33% over an untreated control. Interestingly, the presence of 0.1 wt% the classic stress shocked yeast lysate, Biodynes™ TRF™, improves elastin production by nearly 10% over the untreated control.

**In Vivo – Wrinkle Reduction**

The wrinkle reduction properties of Biodynes™ EMPP were evaluated by conducting an *in vivo* study on 10 subjects. Informed participants applied a control serum to the crow’s feet on one side of the face and a similar vehicle with 1% of Biodynes™ EMPP on the other. Application was done twice daily for 4 weeks. Quantification of cutaneous relief was done using laser profilometry and skin prints.

This method takes into account the three dimensions of the wrinkles to determine geometric parameters such as complexity (visual impact of wrinkles), related to smoothness of skin, expressed in %, maximum or average depth (mm), and wrinkle volume (mm³). These parameters are not detected on the wrinkle itself, but on its print in siliconed rubber (Silflo™). The determination of the geometric parameters was done on both the wrinkle and microrelief (small depressions at the surface of the epidermis) at each surface point.

Each participant’s “print” was taken on both defined zones (crow’s feet) at day 0 and at day 28. Parameter measurements were calculated from the prints to determine the differences in each category from the beginning of the study and the end. The 28 day Wrinkle Study results are shown in Figure 4 as the % change in each category comparing the Biodynes™ EMPP formula to the control.

The results from the microrelief study are not discussed in this document, as they were not significant. Based on the previously discussed *in vitro* work achieved on Biodynes™ EMPP, these results could have been anticipated. Biodynes™ EMPP stimulates the formation of newly synthesized elastin, therefore offers a dermic effect that is directly related to wrinkles and not to microrelief.

**Fig. 5**

Laser Profilometry results of the Wrinkle Study. Changes in treated side [1% Biodynes® EMPP] compared to control side from Day 0 to Day 28. The more negative the results, the more the test material provides an anti-wrinkle [wrinkle reduction observed] effect in that category.

From the data shown, it is clearly evident that the test formula containing 1% Biodynes™ EMPP has an anti-wrinkle effect in all parameters. The most statistically significant results were those obtained for wrinkle volume. The eye serum containing 1% Biodynes™ EMPP was more efficient than the vehicle alone, decreasing wrinkle volume by 17%. This is equivalent to a 12% improvement over control, experienced by 78% of the volunteers.

Biodynes™ EMPP demonstrated an average reduction of 8% in wrinkle depth, or an 11% improvement over control. This positive effect was noticeable on 50% of the panelists. 70% of the volunteers experienced an improvement in wrinkle complexity using the Biodynes™ EMPP formulation, by an average reduction of 24%, a 43% improvement over the control.

Improvements in both wrinkle depth and complexity can be attributed to a smoothing effect on the skin, while improvements in wrinkle volume result in a true anti-aging, anti-wrinkle effect.

---

**Personal Care – Biodynes™ EMPP**

---

---
Conclusions

Biodynes™ EMPP has been specifically developed by manipulation of the nutritional peptone that the yeast is grown in through addition of specific low molecular weight glycosaminoglycans. Using newly developed in vitro testing methods, we have shown that Biodynes™ EMPP stimulates production of soluble elastin. In vivo laser profilometry studies confirm that this stressed yeast lysate affords skin smoothing, line minimizing, anti-wrinkle properties. Biodynes™ EMPP has demonstrated that it will effectively improve the visible signs of aging.

Typical Properties

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appearance</td>
<td>Clear liquid</td>
</tr>
<tr>
<td>Color</td>
<td>Matches standard</td>
</tr>
<tr>
<td>NVM</td>
<td>12% min</td>
</tr>
<tr>
<td>UV</td>
<td>Matches standard</td>
</tr>
<tr>
<td>Odor</td>
<td>Characteristic yeast</td>
</tr>
<tr>
<td>pH</td>
<td>4.5 - 8.0</td>
</tr>
<tr>
<td>Residue on Ignition</td>
<td>7.5% max</td>
</tr>
<tr>
<td>Heavy Metals</td>
<td>less than 20 ppm</td>
</tr>
<tr>
<td>Arsenic</td>
<td>less than 2 ppm</td>
</tr>
<tr>
<td>Microbial Content</td>
<td>500 ppm max, No pathogens</td>
</tr>
<tr>
<td>Recommended Use Level</td>
<td>0.1 - 1.0%</td>
</tr>
</tbody>
</table>

Toxicological Testing Review

<table>
<thead>
<tr>
<th>Test</th>
<th>Result</th>
</tr>
</thead>
<tbody>
<tr>
<td>EpiDerm</td>
<td>Non-Irritating</td>
</tr>
<tr>
<td>EpiOcular</td>
<td>Non-Irritating</td>
</tr>
<tr>
<td>RPT</td>
<td>Non-primary irritant, non-primary sensitizer</td>
</tr>
</tbody>
</table>

References


USA
Lonza Consumer Care
70 Tyler Place
South Plainfield, NJ 07080
Tel +1 908 561 5200

Switzerland
Lonza Ltd
Muenchensteinerstrasse 38
4002 Basel
Tel +41 61 316 81 11

This product information corresponds to our knowledge on the subject at the date of publication and we assume no obligation to update it. It is offered without warranty, and is intended for use by persons who are experienced and knowledgeable in the field and capable of determining the suitability of ingredients for their specific applications. Because we cannot anticipate all variations in actual end-use conditions, we assume no liability and make no warranty in connection with your use of our products or product information. We do not guarantee the efficacy of active ingredients, delivery systems, functional ingredients, rheology modifiers, natural or botanical products, preservative and protection systems or proteins in any specific application or use. The information we provide is not intended to substitute for testing. You should perform your own tests to determine for yourself the suitability and efficacy of ingredients in your application and conditions of use. The information we provide should not be construed as a license to operate under or a recommendation to infringe any patent or other intellectual property right, and you should ensure that your use does not infringe any such rights. Our products are for industrial use only. WE MAKE NO WARRANTY [INCLUDING AS TO MERCHANTABILITY OR FITNESS FOR PURPOSE] OF ANY KIND, EXPRESS OR IMPLIED, OTHER THAN THAT OUR PRODUCTS CONFORM TO THE APPLICABLE PRODUCT SPECIFICATIONS.

© 2014 Lonza Ltd